FIELD: pharmaceutical industry.
SUBSTANCE: group of inventions relates to the pharmaceutical industry, namely to a composition for the prevention or treatment of one or more consequences of a stroke in a mammal and a method for the prevention or treatment of one or more consequences of a stroke in a mammal. The composition for the prevention or treatment of one or more consequences of a stroke in a mammal includes the effective amount of phorbol ester of the formula I or its pharmaceutically acceptable salt, isomer or enantiomer,
where R1 and R2 are selected from a group consisting of hydrogen, hydroxyl, , where an alkyl group contains from 1 to 15 of carbon atoms; , where a lower alkenyl group contains from 1 to 7 carbon atoms; and ; and R3 is hydrogen and , where the specified phorbol ether of the formula I excludes 12-O-tetradecanoyl-phorbol-13-acetate (TPA), where one or more of side effects of a stroke is paralysis, spatial perception disorder, blurred consciousness, left ignoring syndrome, aphasia, problems with coordination and balancing, nausea, vomiting, cognitive disorder, perception disorder, orientation disorder, homonymous hemianopia, impaired mobility or impulsivity. The method for the prevention or treatment of one or more consequences of a stroke in a mammal includes the administration of the composition containing the effective amount of phorbol ether of the formula I or its pharmaceutically acceptable salt, isomer or enantiomer to the specified mammal.
EFFECT: above-described composition is effective for the prevention or treatment of one or more consequences of a stroke in a mammal, where one or more of side effects of a stroke is paralysis, spatial perception disorder, blurred consciousness, left ignoring syndrome, aphasia, problems with coordination and balancing, nausea, vomiting, cognitive disorder, perception disorder, orientation disorder, homonymous hemianopia, impaired mobility or impulsivity.
13 cl, 1 tbl, 10 ex
Title | Year | Author | Number |
---|---|---|---|
COMPOSITIONS AND METHODS OF USE OF PHORBOL ESTERS FOR THE TREATMENT OF STROKE | 2013 |
|
RU2650963C2 |
COMPOSITIONS AND METHODS OF USING PHORBOL ESTERS | 2013 |
|
RU2659684C2 |
COMPOSITIONS AND METHODS FOR APPLYING PHORBOL ESTERS | 2008 |
|
RU2472511C2 |
PHORBOL ESTER COMPOSITIONS AND METHODS OF USING THEM FOR TREATING OR REDUCING DURATION OF CYTOPENIA | 2015 |
|
RU2730998C2 |
PHARMACEUTICAL APPLICATIONS OF LANOST-8,24-DIEN-3-OLS | 2008 |
|
RU2476226C2 |
METHOD FOR ACHIEVING DESIRED GLIAL GROWTH FACTOR 2 PLASMA LEVELS | 2014 |
|
RU2687097C2 |
METHOD OF PROVIDING REQUIRED LEVELS OF GLIAL GROWTH FACTOR 2 IN PLASMA | 2009 |
|
RU2530650C2 |
COMBINATIONS FOR TREATING IMMUNO-INFLAMMATORY DISORDERS | 2002 |
|
RU2322984C2 |
METHODS AND COMPOSITIONS FOR TREATING INFLAMMATION AND ISCHEMIC DAMAGE | 2012 |
|
RU2638807C2 |
NOVEL ANTITUMOR COMPOUNDS | 2003 |
|
RU2356908C2 |
Authors
Dates
2022-07-12—Published
2013-01-18—Filed